How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early‐Stage Neuronal Alpha‐Synuclein Disease

Overview of attention for article published in Annals of Neurology, May 2026

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

news: 1 news outlet
twitter: 2 X users

bluesky: 3 Bluesky users

Readers on

mendeley: 3 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 11,711 followers.

RT @ScienceofPD: An invited editorial explores how the @MichaelJFoxOrg's PPMI programme is enabling the first interventional platform tria…

An invited editorial explores how the @MichaelJFoxOrg's PPMI programme is enabling the first interventional platform trial ("Path to Prevention" or P2P) to test therapies in individuals with Early-Stage Neuronal Alpha-Synuclein Disease https://t.co/JY…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.